Diagnostics Lag Is Holding Back New Therapies, Says Study
A new UCSF analysis published in Science warns that diagnostic development is lagging behind therapeutic breakthroughs because of regulatory and reimbursement gaps. The authors highlight that nearly half of the world’s population—about 47%—has limited or no access to essential tests, undermining the impact of advanced medicines. They cite the lack of predictive tests for GLP‑1 obesity drugs and the high‑cost, under‑covered Alzheimer’s blood assays as concrete examples. The paper calls for coordinated policy reforms that align drug and diagnostic approvals and payment structures.
DualityBio Reports China NMPA Acceptance of BLA for Trastuzumab Pamirtecan in Metastatic HER2+ Breast Cancer
DualityBio announced that China’s National Medical Products Administration has accepted its Biologics License Application for trastuzumab pamirtecan (T‑Pam), an investigational antibody‑drug conjugate targeting HER2‑positive metastatic breast cancer. The submission is backed by interim data from the pivotal Phase III DB‑1303‑O‑3001 trial,...
FDA Probes Abortion Pill Anew After Court Keeps Mail Access Alive
The FDA announced a renewed, accelerated safety study of the abortion pill mifepristone, aiming to complete the review faster than typical academic timelines. The move follows a Louisiana federal judge’s decision to temporarily allow the drug’s distribution by mail while...
Chinese Trial Backs Base-Editing Drug for Thalassaemia
A Chinese investigator‑led trial of CorrectSequence Therapeutics' ex vivo base‑editing drug CS‑101 showed that all five patients with transfusion‑dependent beta‑thalassaemia became transfusion‑independent after a single infusion, with an average cessation time of 16 days and sustained hemoglobin gains over three months....
Sobi Reports Health Canada Approval of Empaveli for C3G and Primary IC-MPGN
Health Canada has granted approval for Empaveli (pegcetacoplan) to treat patients aged 12 and older with C3 glomerulopathy (C3G) or primary immune‑complex membranoproliferative glomerulonephritis (IC‑MPGN). The decision follows the Phase III VALIANT trial, which demonstrated a 68% reduction in proteinuria, stabilization...
Surface‑Engineered Primer Immobilization Enables Simplified and Affordable Nucleic‑Acid Capture for Molecular Diagnostics in Sub‑Saharan Africa
A study introduces a silica‑free nucleic‑acid capture method using polycarbonate surfaces modified with acetone‑UV pretreatment and branched polyethyleneimine linkers. The treatment doubles surface carboxyl groups, and BPEI chemistry attaches about 2.6 times more primers than conventional ethylenediamine links. Fluorescence assays confirm...
AllRock Bio Begins Patient Dosing in Phase IIa ROCSTAR Trial
AllRock Bio has begun dosing the first patients in its Phase IIa ROCSTAR trial of ROC‑101, an oral pan‑ROCK inhibitor aimed at pulmonary hypertension. The multi‑center study will enroll up to 30 pulmonary arterial hypertension (PAH) patients and 10 interstitial lung...
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
Oncology drug development is shifting toward precision immunotherapies, with biomarkers driving patient selection and trial efficiency. Experts at a Caidya webinar highlighted two trends: novel combination regimens and early integration of biomarker strategies, including companion diagnostics. Early biomarker adoption can...
Gan & Lee and JW Pharmaceutical Agree on Bofanglutide Commercialisation
Gan & Lee Pharmaceuticals has signed an exclusive licence with JW Pharmaceutical to develop and commercialise the GLP‑1RA bofonaglutide in South Korea. JW will receive a $5 million upfront payment and up to $76.1 million in milestones, bringing total potential value to...
FDA Approves Higher Dose Nusinersen for Spinal Muscular Atrophy
The FDA has approved a higher‑dose regimen of nusinersen (Spinraza) for spinal muscular atrophy, updating both the loading and maintenance phases. The new schedule delivers two larger injections two weeks apart, followed by maintenance doses every four months. Approval follows...
Addressing Pain Points in Organoid Sorting: The Orgadroid
Visienco, a Swiss life‑sciences startup, unveiled the Orgadroid—an automated platform that combines precision robotics with AI‑driven microscopy to sort and classify organoids. The organoid market is forecast to reach $15.01 billion by 2031, growing at a 22.43% CAGR, but manual handling...
Telix Reports US FDA Acceptance of NDA for TLX101-Px (Pixclara) in Glioma Imaging
Telix Pharma announced that the U.S. FDA has accepted the resubmitted New Drug Application for TLX101‑Px, marketed as Pixclara, an investigational 18F‑FET PET imaging agent for glioma detection in adults and children. The agency set a PDUFA action date of...
Amgen’s Lung Cancer Drug Tarlatamab Wins China Approval
Amgen’s bispecific antibody tarlatamab, marketed in the U.S. as Imdelltra, has received approval from China’s National Medical Products Administration. The drug is designed for adults with extensive‑stage small cell lung cancer that has progressed despite chemotherapy. Amgen will commercialize the...
Multi-Agent AI Delivers Reliable and Scalable Insights for Single-Cell Omics
Nygen Analytics, a Lund‑based startup founded by computational genomics expert Parashar Dhapola, is deploying multi‑agent AI to streamline single‑cell omics analysis. The platform automates cell‑type annotation, handling millions of cells while reducing error rates that can misguide drug discovery. By...
Kymera Therapeutics Reports Gilead’s Option Exercise to License KT-200, a CDK2 Molecular Glue Degrader
Gilead Sciences exercised its option to exclusively license KT‑200, a first‑in‑class oral CDK2 molecular‑glue degrader, from Kymera Therapeutics. The transaction triggers a $45 million milestone payment, with Kymera eligible for up to $750 million in additional milestones and tiered royalties. Gilead will...
Iron‐Based Metal‐Organic Framework MIL‐100(Fe) Regulates Keloid Scarring in a Humanized Keloid Model
The study shows iron‑based metal‑organic framework MIL‑100(Fe) nanoparticles are highly biocompatible, rapidly taken up by keloid fibroblasts, and selectively inhibit the TGF‑β/SMAD pathway, reducing collagen I, collagen III, and P4HA1 expression. In vitro experiments maintained >90% cell viability and curtailed...
Imagene AI Partners with Daiichi Sankyo to Advance Multimodal Biomarker Discovery in Oncology
Imagene AI has teamed up with Daiichi Sankyo to use its OI Suite, powered by the CanvOI foundation model, for multimodal biomarker discovery in oncology. The collaboration will integrate H&E and IHC whole‑slide images with molecular and clinical data to...
RxERP Hub Targets Pharma’s Serialization Blind Spots
RxERP unveiled the RxERP Hub, upgrading its serialized platform into a full‑scale infrastructure for the pharmaceutical supply chain. The Hub adds unit‑level audit logging that records every transaction—from receiving to dispensing—creating a real‑time, immutable trail. This turns serialization from a...
In a First, a Drugmaker’s Lawsuit Challenges HRSA’s 340B Patient Definition
AbbVie Inc. has filed a lawsuit in Washington, D.C. challenging the Health Resources and Services Administration’s (HRSA) 30‑year‑old guidance on who qualifies as a “patient” under the 340B drug pricing program. The drugmaker argues the guidance is overly broad, allowing...
AI Diffusion Models Tailor Drug Molecules to Custom-Fit Protein Targets, Speeding Drug Development and Evaluation
University of Virginia researchers unveiled YuelDesign, an AI diffusion‑model platform that simultaneously generates drug‑like molecules and their flexible protein binding pockets. Complementary tools YuelPocket and YuelBond locate precise binding sites and ensure chemically realistic bonds, respectively. Early validation on the...
Gilead and Roche Bet on Protein Degraders for Their Cancer Drug Pipelines
Gilead exercised its option to license Kymera Therapeutics' CDK2 molecular‑glue degrader KT‑200, triggering a $45 million payment and opening a potential $665 million milestone path, with an IND target of 2027. Roche paid $20 million upfront to C4 Therapeutics to co‑develop degrader‑antibody drug...
Recalls of Angiotensin II Receptor Blockers (ARBs) Including Valsartan, Losartan and Irbesartan
The FDA has issued recalls for certain generic angiotensin II receptor blockers—including valsartan, losartan and irbesartan—after detecting nitrosamine impurities such as NDMA, NDEA and NMBA. These contaminants are probable carcinogens and were traced to manufacturing processes of the active pharmaceutical ingredient....
Mississippi 340B Law Upheld by Appeals Court in Two Cases
On April 9, 2026, the U.S. Court of Appeals for the Fifth Circuit upheld Mississippi’s law that protects 340B drug pricing for contract‑pharmacy arrangements. The court affirmed district‑court rulings rejecting injunction requests from Novartis, the Pharmaceutical Research and Manufacturers of America...
Commissioner's National Priority Voucher (CNPV) Pilot Program
The FDA launched the Commissioner’s National Priority Voucher (CNPV) pilot in June 2025 to fast‑track drug and biologic applications that align with five U.S. national health priorities. The program promises a 1‑ to 2‑month review window, far shorter than the...
BBB Access Route via Proteomic Vascular Mapping
Researchers led by Jiefu Li at the Howard Hughes Medical Institute have unveiled an in‑vivo proteomic method that tags and isolates proteins on the luminal surface of blood vessels. By perfusing a lectin‑conjugated peroxidase, they biotinylate adjacent proteins, enabling mass‑spectrometry...
Tirzepatide Outperforms Dulaglutide on Cardiorenal Outcomes in High-Risk Diabetes
A post‑hoc analysis of the SURPASS‑CVOT trial shows tirzepatide (Mounjaro) delivering superior cardiorenal protection compared with dulaglutide in patients with type 2 diabetes and established cardiovascular disease. Over a median 47‑month follow‑up, the composite of mortality, myocardial infarction, stroke, coronary revascularization,...
With Cash to Burn and Patent Cliffs Looming, Pharma Giants Are Buying More Biotechs
Big‑pharma M&A activity has accelerated in 2026, with 14 deals over $500 million in Q1 alone—nearly half the total deals recorded in 2025. Gilead’s $7.8 billion purchase of Arcellx and Eli Lilly’s $6.3 billion acquisition of Centessa illustrate a push into cell‑therapy, autoimmune and...
Post-Hoc Live: Biopharma M&A Is Back, with Barclays' Emily Field
Biopharma mergers and acquisitions are experiencing one of their strongest periods in years, as major pharmaceutical firms rush to absorb smaller biotech innovators. In a Post‑Hoc Live interview, Emily Field, head of U.S. biopharma‑catalytics equity research at Barclays, and deals...
How to Build an Effective Environmental Monitoring Program Under Annex 1
The EU GMP Annex 1 revision reclassifies Environmental Monitoring (EM) from a compliance checkbox to a core element of sterile‑product contamination control. Legacy, sampling‑driven EM programs no longer satisfy regulators; they must be rebuilt on risk‑based assessments, integrated with cleaning, HVAC...
States Continue to Advance New PBM and Drug Pricing Legislation in 2026
State lawmakers in Virginia and Ohio are moving ahead with aggressive pharmacy‑benefit‑manager (PBM) reforms in 2026. Virginia’s Affordable Medicine Act would apply the Inflation Reduction Act’s maximum fair price ceiling to state‑regulated health plans and require PBMs to report fees,...
Compounding Research
The FDA has launched multiple research collaborations to evaluate the safety and efficacy of compounded drug products. Partnerships with the National Academies of Science, Engineering, and Medicine (NASEM) focus on bioidentical hormone therapy and topical pain cream ingredients, while its...
Human Drug Compounding Policies and Rules
The FDA has released a series of guidance documents, interim policies, and Federal Register notices spanning 2014‑2025 that shape human drug compounding under sections 503A and 503B of the FD&C Act. Recent 2025 interim policies address bulk drug substance use for both...
Easier Access to GLP-1s Sends Usage Far Beyond Original Predictions
Morgan Stanley Research now projects that 55 million U.S. consumers will be using GLP‑1 drugs by 2035, up from its earlier estimate of 33 million. The surge is driven by Medicare coverage and the introduction of oral formulations. Despite higher discontinuation and...
British Heart Foundation Receives Largest Donation
The British Heart Foundation received a £6 million (≈$7.7 million) donation from the Garfield Weston Foundation, the charity’s largest single gift ever. The money will bolster the BHF’s Centre of Research Excellence in Advanced Cardiac Therapies, a joint venture with the Medical...
Re: Glucagon-Like Peptide-1 Receptor Agonists and Risk of Substance Use Disorders Among US Veterans with Type 2 Diabetes: Cohort Study
A BMJ cohort study emulating a target trial found that US veterans with type 2 diabetes who were prescribed glucagon‑like peptide‑1 (GLP‑1) receptor agonists experienced significantly fewer incident substance‑use disorders (SUDs) and related adverse events compared with those on sodium‑glucose...
Scientists Are Finally Unlocking a Cancer Treatment’s Full Potential
German hematologist Fabian Müller applied experimental CAR‑T cell therapy to a 47‑year‑old woman suffering from three severe autoimmune diseases, achieving remission and eliminating her need for transfusions. CAR‑T, originally developed for cancer, is now delivering months‑to‑years of remission in multiple...
STAT+: 5 Years After Lupus Breakthrough, CAR-T Is Still Surprising Autoimmunity Researchers
Five years after a pioneering CAR‑T treatment rescued a teenage lupus patient, the therapy has sustained remission and reshaped expectations for autoimmune disease management. The case, led by German rheumatologist Georg Schett, proved that engineered T cells could safely target...
Long-Term Bimekizumab Data Confirm Sustained Efficacy, Consistent Safety in Hidradenitis Suppurativa: Steven Daveluy, MD
Long‑term data from the BE HEARD 1 and BE HEARD 2 trials show that 86.1% of hidradenitis suppurativa patients treated with bimekizumab remained flare‑free over a three‑year period. The biologic’s safety profile stayed consistent from week 16 through year 3, with no new signals detected. Early...
Eli Lilly’s Mounjaro Loses Ground to Less-Expensive Semaglutide Generics & Innovator Novo Nordisk’s Products
Eli Lilly’s tirzepatide brand Mounjaro saw sales dip to ₹114 crore in March, down from ₹135 crore in February, as low‑cost generic semaglutide entered the Indian market. The generics, launched by 13 firms across 26 SKUs, are priced 50‑80% below Novo Nordisk’s Ozempic, Wegovy...
Makena (Hydroxyprogesterone Caproate Injection) Information
The FDA’s Center for Drug Evaluation and Research has proposed withdrawing approval of Makena, a hydroxyprogesterone caproate injection originally granted accelerated approval in 2011 to reduce preterm birth risk. A confirmatory trial—four times larger than the pivotal study—failed to demonstrate...
Pure Indulgence Aesthetics - 723267 - 04/01/2026
The FDA issued a warning letter to Pure Indulgence Aesthetics after a December 2025 inspection revealed serious DSCSA violations. The spa dispensed significantly more Botox units than it purchased from AbbVie, suggesting use of unauthorized sources, and was found with...
Office of Prescription Drug Promotion (OPDP) News
The FDA’s Office of Prescription Drug Promotion issued a final guidance on Jan 6 2025 that clarifies its enforcement policy for firm‑initiated communications of scientific information on unapproved uses (SIUU) to health‑care providers. The document specifies permissible source publications—journal reprints, clinical practice...
PharmaShots Magazine-April-2026 Edition
The April 2026 edition of PharmaShots spotlights AI’s rapid infiltration into pharmaceutical compliance, turning regulatory oversight into a continuous, data‑driven process. It also details a wave of high‑value deals, with Biogen, Eli Lilly and Merck acquiring AI‑centric assets and forging partnerships...
Prescription Drug User Fee Amendments
The FDA sent FY2025 clean‑up and FY2026 PDUFA fee invoices, with payments due Jan 20 2026 and Nov 13 2025 respectively. FY2026 fee rates rose to $4.68 million for full applications, $2.34 million for half‑fees, and $442,213 for annual program fees. Effective Oct 1 2025 the agency will...
Avalyn Plots IPO to Push Inhaled Pulmonary Fibrosis Pipeline Through Clinic
Avalyn Pharma announced its intent to launch an IPO on Nasdaq under the ticker AVLN, though the number of shares and target raise remain undisclosed. The company will channel the proceeds into advancing its inhaled pulmonary‑fibrosis pipeline, beginning with AP01,...
Sir Demis Hassabis Wants to Automate Drug Design
DeepMind CEO Demis Hassabis reiterates his ambition to automate drug design using artificial intelligence. After AlphaFold earned the 2024 Nobel Prize in Chemistry for protein‑folding predictions, DeepMind is now channeling its expertise into generative models that can design therapeutic molecules...
Mysterious 'Compound X' Clears Toxic Parkinson’s Proteins From Brain
Researchers at Swinburne University disclosed that an undisclosed molecule, dubbed compound X, eliminated toxic protein clumps linked to Parkinson's disease in mice. The treatment activated the brain's glymphatic waste‑clearance system, resulting in measurable gains in balance and overall mobility. While the...
Innovent’s CDMO Gets Green Light to Make Biologics at Large Chinese Plant
Innovent Biologics’ CDMO, Altruist Biologics, received its first 20,000‑liter biologics production license from China’s NMPA for the Hangzhou plant, marking the country’s inaugural facility of this scale. The site, equipped with four 20,000‑liter bioreactors, will be expanded to 172,000 liters, complementing...
C4 Therapeutics and Roche Enter Oncology Collaboration Worth Over $1B to Develop DAC with Payload
C4 Therapeutics and Roche have signed a multi‑billion‑dollar partnership to develop degrader‑antibody conjugates (DACs) for cancer treatment. The deal launches two undisclosed oncology programs, with C4 providing its Torpedo degrader payload platform and Roche handling antibody selection, conjugation, and downstream...
How to Use Real-World Data to Improve Drug Development, Starting with the Patient Journey
A new eBook from PurpleLab and MedCity News highlights how real‑world data (RWD) can expose hidden gaps in the non‑small cell lung cancer (NSCLC) patient journey, such as missed biomarker testing and transportation barriers. Recent state legislation now requires insurers...